Long-term monitoring of a new hydrocortisone pill for adrenal hyperplasia
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tracks adults with congenital adrenal hyperplasia (a condition where the body can't make enough cortisol) who switch to a new form of hydrocortisone called modified-release. It looks at how well the medication works over time and its effects on daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have a confirmed genetic diagnosis of 21-hydroxylase deficiency (the most common type of congenital adrenal hyperplasia).
- You are planning to switch from your current steroid medication to a modified-release hydrocortisone pill as part of normal care.
- Your current steroid and salt-balance medications must be stable before you switch.
- You are not pregnant or breastfeeding, and you don't have any severe uncontrolled medical or mental health conditions.
- You don't take steroids for other conditions and haven't had surgery to remove both adrenal glands.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a once-daily hydrocortisone tablet works as well as standard steroid treatment for adults with congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. It aims to improve how safely and conveniently hormone replacement is taken each day.
This study tests a new medication for children with classic congenital adrenal hyperplasia (CAH). It aims to see if the drug helps better control hormone levels and reduce the need for high doses of current steroid medicines.
This trial tests a new medicine (NBIP-01435) to see if it helps adults with classic congenital adrenal hyperplasia better manage their condition. The goal is to improve hormone levels and potentially allow for lower steroid doses.
This study tests a new drug, atumelnant, for adults with classic congenital adrenal hyperplasia (CAH) caused by 21-OHD. It aims to see if it can help control hormone levels while allowing lower doses of current steroid medications.
This study aims to improve the transition from pediatric to adult care for young people with congenital adrenal hyperplasia (CAH). It will test a special transition program and may help make the shift to adult care smoother and more supported.
This study tests a new drug called OMS1620 to see if it is safe and how the body processes it. It is for healthy adults who may join to help find out if the drug could be used for future treatments.
Hear when a new CAH - Congenital Adrenal Hyperplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.